Pfizer to develop Akcea/Ionis’ Antisense Drug for up to $1.5bn
October 8, 2019Manufacturing and Production
Pfizer and Akcea Therapeutics have entered into an exclusive worldwide licensing agreement for Akcea’s phase 2 cardiovascular and metabolic candidate …
Johnson & Johnson win FDA Breakthrough status for cancer drug Zejula
October 7, 2019Sales and Marketing
The US FDA has granted breakthrough therapy designation for Johnson & Johnson’s Zejula (niraparib) for the treatment of metastic prostate …
Gilead appoints Merdad Parsey as Chief Medical Officer
October 7, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Gilead Sciences have announced that Merdad Parsey will join the company as Chief Medical Officer, effective November 1st. Dr Parsey …
Breaking through limits in lung cancer: Introducing the Lung Ambition Alliance
October 7, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, Lung Ambition Alliance, feature, lung cancer, pharma
Lung cancer kills more patients than any other variety of cancer, accounting for around a fifth of all cancer-related deaths …
Sacklers made up to $13 billion in profits from Purdue Pharma
October 7, 2019Sales and Marketing
New court records filed in Purdue Pharma’s ongoing bankruptcy case show that the owners, the Sackler family, received $12 billion …
Scotland approves first-line NHS use of MSD’s Keytruda combo for advanced non-small cell lung cancer
October 7, 2019Sales and Marketing Cancer, NHS, Scotland, Scottish Medicines Consortium, UK, keytruda, lung cancer, pharma
The Scottish Medicines Consortium (SMC) has announced its decision to accept MSD’s blockbuster immunotherapy Keytruda (pembrolizumab) in combination with pemetrexed …
Pfizer reports positive phase 3 data in atopic dermatitis
October 7, 2019Sales and Marketing
Pfizer has announced top-line results from a second Phase 3 study evaluating the efficacy and safety of its oral JAK1 …
Sarepta’s investigational gene therapy shows strength in limb-girdle muscular dystrophy Type 2E
October 7, 2019Research and Development, Sales and Marketing muscular dystrophy, pharma, sarepta
Sarepta Therapeutics has revealed positive new data for its investigational gene therapy SRP-9003 in the treatment of limb-girdle muscular dystrophy …
Galderma wins FDA approval for new retinoid molecule acne treatment AKLIEF
October 7, 2019Sales and Marketing
Galderma, a global leader in skin health, has announced that the FDA has approved the First New Retinoid Molecule for …
Johnson & Johnson commits $500m to end HIV and TB Epidemics
October 4, 2019Medical Communications, Research and Development
Johnson & Johnson have announced it has committed to ensuring more than $500 million is dedicated to R&D delivery programs …
Top Ten most popular articles on Pharmafile.com this week
October 4, 2019Medical Communications
Another week comes to an end at Pharmafile and we run down with the top 10 articles for the week. …
Arbutus Biopharma moves to terminate development of chronic hepatitis B therapy after trial failure
October 4, 2019Medical Communications, Research and Development Arbutus Biopharma, hepatitis B, pharma
Arbutus Biopharma has announced its decision to terminate the development of its oral capsid inhibitor, known as AB-506, in the …
UK watchdog finds drug firms colluded to hike essential NHS medication by 1,800%
October 4, 2019Medical Communications
The UK’s Competition and Markets Authority (CMA) has provisionally found that three drug firms signed an illegal agreement which led …
FDA approves single-use auto-injector form of IL-5 inhibitor Fasenra
October 4, 2019Medical Communications, Sales and Marketing AstraZeneca, FDA, Fasenra, pharma
AstraZeneca is celebrating as the FDA announced the approval of its IL-5 inhibitor Fasenra (benralizumab) in a pre-filled, single-use auto-injector …
FDA approves second PrEP drug to prevent HIV infection
October 4, 2019Medical Communications
The US FDA has approved Gilead’s Descovy (emtricitabine/tenofovir alafenamide) as a second pre-exposure prophylaxis (PrEP) drug in at-risk adults and …
Servier gains non-Hodgkin lymphoma drug from CTI BioPharma
October 3, 2019Medical Communications, Sales and Marketing
French pharma-giant Servier has purchased the medication Pixuvri, indicated for the treatment of non-Hodgkin B-cell lymphoma, from US-based CTI BioPharma. …
GSK Chief Emma Walmsley voices support for equal pay campaign
October 3, 2019Medical Communications Emma Walmsley, GSK, GlaxoSmithKline, pharma
GlaxoSmithKline Chief Emma Walmsley has joined the chorus of more than a hundred of the UK’s most successful female business …
Novartis selects Microsoft for AI drug development
October 3, 2019Research and Development
Novartis has begun an alliance with Microsoft to leverage the latter’s artificial intelligence (AI) technology for the discovery, development and …
NICE rejects Roche’s immunotherapy Tecentriq in unresectable metastatic triple A breast cancer
October 3, 2019Sales and Marketing Cancer, NICE, Roche, breast cancer, pharma, tecentriq
NICE has revealed its decision not to approve Roche’s immunotherapy Tecentriq (atezolizumab) for use on the NHS in England and …
Government issues first serious shortage protocol to combat lack of the antidepressant fluoxetine
October 3, 2019Manufacturing and Production
The Department of Health and Social care has brought in measures to allow pharmacists to supply alternative strengths of fluoxetine …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
